On the other hand, in vincristine-resistant gastric cancer cell line SGC7901/VCR, treatment with lenalidomide enhanced DNMT3A expression, increased DNA methylation and downregulated Notch2 expression, providing a limited cytotoxic effect and suggesting this agent as a therapeutic approach in drug-resistant gastric cancer [273]. Here, DNMT3A is linked to gastric cancer.